A common playbook has emerged for launching a direct-to-consumer health brand: build the website and patient acquisition flow, run the marketing yourself, and plug the clinical side into a third-party platform that connects your brand to independent, licensed providers who handle the medical evaluation and prescribing.
This is a genuinely efficient way to launch. It also puts a non-clinician entrepreneur, often with no license, no healthcare background, and no experience with healthcare regulation, at the center of a heavily regulated business. The platform handles the parts that obviously require a license. What gets underappreciated is how much legal exposure sits on the entrepreneur’s side, in the parts that look like ordinary marketing and operations.
Here is what actually matters if this is the model you’re building.
You Cannot Own or Control the Practice of Medicine, Even If You Never Touch a Prescription
The corporate practice of medicine doctrine restricts non-licensed individuals and entities from owning or controlling a medical practice. Most entrepreneurs assume it doesn’t apply to them because they never see a patient or write a prescription. That’s incomplete. The doctrine looks at control, not just clinical activity, and control can show up in places that feel purely operational:
- Do you influence which patients get “pre-approved” for treatment based on intake answers, before a licensed provider reviews the case?
- Do you set pricing or promotional offers in a way that pressures the platform’s providers to prescribe at a certain rate to hit revenue targets?
- Does your contract with the platform give you any say over which providers are used, how they’re supervised, or how clinical protocols are set?
If the answer to any of these is yes, you may be exercising control over clinical operations that regulators would view as encroaching on the corporate practice of medicine, regardless of who holds the prescription pad. The safer structure keeps a hard, documented line between your company’s role (marketing, technology, patient acquisition, brand) and the platform’s role (clinical evaluation, prescribing, protocols), reflected in the actual contract, not just in how you pitch the business.
How You Get Paid Matters More Than People Realize
This one catches the most entrepreneurs off guard. Many states, including Florida, prohibit fee-splitting: sharing professional medical fees with a non-licensed person or entity. If your compensation is a percentage of prescription revenue, a per-prescription fee, or anything that functions like a cut of the clinical fee, you may be structuring an illegal fee-split, even as the marketing side of the business.
The safer structure is to be paid for what you actually do: a flat technology or marketing fee, a fee tied to patient acquisition or ad spend, or a subscription arrangement, rather than compensation that scales with the volume or value of prescriptions written.
Your Marketing Creates Legal Exposure That’s Yours, Not the Platform’s
If you run the ads and put the copy out, you are very likely the party legally responsible for the accuracy of the health and treatment claims made to consumers, even though you didn’t write the prescription.
A few areas worth specific attention:
- Health claims and testimonials. Efficacy claims, before-and-after content, and patient testimonials are subject to FTC substantiation requirements. “Results not typical” disclaimers do not, on their own, fix an unsubstantiated claim.
- “Pre-approval” and checkout language. If your funnel says a patient is “pre-approved” before a licensed provider has reviewed the case, or that a card “will only be charged if prescribed” when that isn’t how your processing works, that gap between representation and reality is exactly what draws FTC and state attorney general scrutiny.
- Prescription drug advertising rules. If your marketing names specific medications, particularly categories like GLP-1s, hormone therapy, or controlled substances, additional advertising rules can apply around risk disclosure and fair balance, on top of general consumer protection law.
- State-specific telehealth disclosure requirements. A number of states require specific disclosures on a telehealth website, such as identifying that the service is delivered via telehealth or disclosing the treating provider’s licensure. These requirements typically fall on whoever operates the patient-facing website, which in this model is you, not the clinical platform.
Extra Exposure If You’re in the GLP-1 or Compounded Medication Space
If your brand markets weight loss or hormone treatments involving compounded semaglutide, tirzepatide, or similar drugs, FDA has been especially active here recently, and some enforcement has landed directly on telehealth companies and their marketing, not just compounding pharmacies. A few points to build into your compliance thinking:
- Some ingredients cannot legally be compounded at all because they do not include components of any FDA-approved drug and cannot lawfully be used in compounding under federal law. If your platform or supplier is offering these types of drugs, that’s not a gray area to manage carefully, it’s a product your brand should not be marketing.
- FDA has issued warning letters directly to telehealth companies, including for DTC marketing of unapproved drugs. Enforcement reaches the marketing and brand layer, not just the compounding pharmacy. As the entrepreneur running the website and ad campaigns, that exposure sits with you.
- Avoid any claim that a compounded drug is “the same as” the FDA-approved version. Compounded drugs are not FDA-reviewed for safety, effectiveness, or quality, and FDA has specifically flagged this type of equivalence claim as a red flag it watches for.
- Compounded drugs are only appropriate when a patient’s medical need genuinely can’t be met by the FDA-approved product, such as a supply shortage or a documented clinical reason. A model built around compounded versions being cheaper or more convenient, rather than medically necessary, sits closer to the practices FDA has been warning about.
- FDA’s consumer red-flag list doubles as a self-audit for your funnel. Deep discounts that seem too good to be true, no meaningful screening before a prescription, and no licensed provider available after purchase are all things FDA tells consumers to watch for. If your patient journey matches several, treat it as a compliance signal, not just a customer-experience one.
The Bottom Line for Entrepreneurs in This Model
Splitting the business this way, entrepreneur handles brand and patient acquisition, platform handles licensed clinical delivery, is a legitimate and increasingly common way to launch. But “the platform handles the medical stuff” is not the same as “the entrepreneur has no medical-adjacent legal exposure.” Corporate practice of medicine, fee-splitting, advertising liability, and health data privacy all reach into the entrepreneur’s side, often in ways that aren’t obvious until a regulator or plaintiff’s attorney points them out.
If you’re building a DTC health brand and structuring a relationship with a third-party clinical platform, this is exactly the kind of structure and contract review worth doing before launch.
This article is for general informational purposes only and does not constitute legal or tax advice. Every practice’s situation is different, and the facts of your arrangement matter. Please contact our office to discuss your specific circumstances.